Quick Answer
Verrica Pharmaceuticals Inc. reported Diluted EPS of $1.68 per share (loss) for fiscal year 2025.
Verrica Pharmaceuticals Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.68 | +88.6% |
| 2024 | -$14.78 | -898.6% |
| 2023 | -$1.48 | -105.6% |
| 2022 | -$0.72 | +44.6% |
| 2021 | -$1.30 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.03 | +99.4% | -250.0% |
| June 30, 2025 | $0.02 | +100.5% | +120.0% |
| March 31, 2025 | -$0.10 | +77.3% | +98.0% |
| September 30, 2024 | -$4.88 | -803.7% | -31.9% |
| June 30, 2024 | -$3.70 | -1441.7% | -740.9% |
| March 31, 2024 | -$0.44 | -193.3% | +18.5% |
| September 30, 2023 | -$0.54 | — | -125.0% |
| June 30, 2023 | -$0.24 | +35.1% | -60.0% |
- Verrica Pharmaceuticals Inc. showed an increase of +88.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Verrica Pharmaceuticals Inc.’s diluted eps has declined by 29.2% (from $1.30 per share (loss) to $1.68 per share (loss)).
- The most recent figure is from Verrica Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: